Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

NCT06862453 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT06862453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06862453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
Lead sponsor
Sanaria Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 12, 2026
Completion date
December 30, 2026
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria falciparum